Old Web
English
Sign In
Acemap
>
Paper
>
O23 Ixekizumab (IXE) vs. adalimumab (ADA) for the treatment of PSA: 52-week efficacy and safety outcomes
O23 Ixekizumab (IXE) vs. adalimumab (ADA) for the treatment of PSA: 52-week efficacy and safety outcomes
2020
Christopher J. Edwards
Andrew J Bradley
Mani H Nassab
Burkhard Möller
Klaus P Machold
Christophe Sapin
Roberto Ranza
Soyi Liu-Léage
Keywords:
C-reactive protein
Prostate-specific antigen
Randomization
Medicine
Adalimumab
Psoriasis
Psoriasis Area and Severity Index
Physical therapy
Surrogate endpoint
Ixekizumab
Internal medicine
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
1
Citations
NaN
KQI
[]